We partner with a range of clients from large pharmaceutical companies to biotechs to assist them in the development of new medicines for respiratory diseases.

Pulmotect, Inc.

Pulmotect, Inc.

Our experience working with VirTus was terrific. They were easy to interact with, collaborative, and provided helpful advice and information at every turn throughout the clinical trial.BRENTON SCOTT, PRESIDENT AND COO, PULMOTECT, INC.Pulmotect, Inc.Virtus Respiratory...

Apollo Therapeutics

Apollo Therapeutics

Apollo TherapeuticsVirtus are working with Apollo Therapeutics on pre-clinical studies working towards the world’s first rhinovirus vaccine.Apollo TherapeuticsVirtus are working with Apollo Therapeutics on pre-clinical studies working towards the world’s first...

Got any questions? Email info@virtus-rr.com or call us on 0207 554 5855

%

INFECTION RATE

The overall infection rate of our current stock of rhinovirus is 82% in asthmatics, COPD and healthy volunteers.

Get in touch

Want to find out more how we can help you develop the next block-buster medicine in asthma or COPD? Get in touch.

Consent(Required)

Keep Updated With Our Progress

Keep up with the latest results, news and other headlines from Virtus Respiratory Research.